Phase 1 Study of BA3071, an Anti–ctla-4 Conditionally Active Biologic, in Combination with Nivolumab in Advanced Solid Tumors.
Journal of Clinical Oncology(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined